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A novel rapid-onset high-penetrance plasmacytoma mouse model
driven by deregulation of cMYC cooperating with KRAS12V in
BALB/c mice
Y Hu1, M Zheng2, R Gali3, Z Tian1, G Topal Go¨rgu¨n1, NC Munshi1, CS Mitsiades1 and KC Anderson1
Our goal is to develop a rapid and scalable system for functionally evaluating deregulated genes in multiple myeloma (MM).
Here, we forcibly expressed human cMYC and KRAS12V in mouse T2 B cells (IgMþB220þCD38þ IgDþ ) using retroviral transduction
and transplanted these cells into lethally irradiated recipient mice. Recipients developed plasmacytomas with short onset (70 days)
and high penetrance, whereas neither cMYC nor KRAS12V alone induced disease in recipient mice. Tumor cell morphology and cell
surface biomarkers (CD138þB220 IgMGFPþ ) indicate a plasma cell neoplasm. Gene set enrichment analysis further conﬁrms
that the tumor cells have a plasma cell gene expression signature. Plasmacytoma cells inﬁltrated multiple loci in the bone marrow,
spleen and liver; secreted immunoglobulins; and caused glomerular damage. Our ﬁndings therefore demonstrate that deregulated
expression of cMYC with KRAS12V in T2 B cells rapidly generates a plasma cell disease in mice, suggesting utility of this model both
to elucidate molecular pathogenesis and to validate novel targeted therapies.
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INTRODUCTION
Multiple myeloma (MM) is a B-cell neoplasm characterized by
accumulation of monoclonal plasma cells.1 Neoplastic transformation
in MM is associated with genomic and epigenetic dysregulation.2
Previous studies have revealed that 40% of MM harbor chromosome
translocations, including CCND1, CCND2, cMAF, MAFB and FGFR3/
WHSC1, with immunoglobulin heavy chain (IgH).3 Deletions of
chromosome 13 are frequently detected in early and late stage MM.4
During disease progression, genetic lesions accumulate, including
mutations of NRAS and KRAS, overexpression of cMYC and
downregulation of P53.5 Using whole-genome sequencing and
whole-exome sequencing,6 more genetic lesions have been
identiﬁed. Thus, it is critical to develop a short latency in vivo
model to functionally evaluate the roles of these dysregulated genes
in MM pathogenesis.
Mouse models both facilitate evaluation of the roles of genetic
lesions detected in MM and provide for assessing therapeutic
agents. The earliest mouse model for MM was induced by
intraperitoneal injection of mineral oil, adjuvant and alkanes in
BABL/c mice. These mice develop plasmacytomas at 200 days post
injection;7 however, plasmacytoma cells typically grow locally at
the site of injection and rarely metastasize to bone marrow (BM).
Widely used models now include xenograft models of MM
generated by subcutaneous injection of human MM cell lines or
primary human MM cells into SCID gamma mice. Particularly
useful is the SCID-hu model, which is made by directly injecting
MM cell lines or patient MM cells into human fetal bone implanted
subcutaneously in SCID mice.8 This model provides three-
dimensional bone-like scaffolds to mimic the human MM
microenvironment and has been used to both assess preclinical
drugs and study MM pathogenesis. Another mouse model has
been developed by transferring 5T2MM or 5T33MM mouse MM
lines into syngeneic recipient mice. These mouse MM lines were
established from aged C57BL/KaLwRij mice, which spontaneously
develop a plasmacytoma with a low frequency and along with an
osteolytic bone disease. These cells can be labeled with bio-trace
marker, such as luciferase9 or green ﬂuorescent protein (GFP),10 for
in vivo imaging. A similar model was recently developed by
intravenous injections of an in vivo-selected MOPC315 cell line
into BALB/c mice.11 Several transgenic mouse models have been
developed based on expression of cMYC under control of an Ig
light chain gene,12 XBP-1,13 cMAF14 or cMYC15 under the control
of the Ig VH promoter and enhancer elements. These models
recapitulate characteristics of MM; however, they are technically
challenging and time consuming with long latency times and do
not allow for evaluating multiple gene functions at a time.
A retroviral transduction/transplantation mouse model can over-
come these limitations of transgenic mouse models as retroviral vectors
can be used to overexpress or silence multiple gene(s) in target cells in
a temporal sequence.16 Retroviral transduction/transplantation mouse
models have been widely used to study acute myeloid leukemia,17
chronic myeloid leukemia,18 B-cell acute lymphoid leukemia19 and the
majority of myeloproliferative neoplasms.20 Based on previous
studies,12 we hypothesized that retroviral delivery of cMYC into a
later stage B-cell subset might induce plasmacytomas in mice. MYC
requires the cooperation or complementation with other oncogenes,
such as v-H-ras or v-raf, for transformation.21 We here therefore
introduced KRAS (KRAS12V) mutation to complement the function of
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cMYC in tumorigenesis. With this strategy, we generated a rapid-onset
high-penetrance plasmacytoma mouse model by enforced expression
of cMYC and KRAS12V in later transition (T2) B-cell subset. This model
provides a rapid tool to functionally evaluate genes in MM
pathogenesis, as well as evaluate novel targeted therapies.
MATERIALS AND METHODS
DNA constructs
All PCR products were cloned into T-easy vector (Promega BioSystems,
Sunnyvale, CA, USA) and completely sequenced to verify the correct
reading frame.
To make a subclone vector MSCVm, MSCV-IRES-eGFP (MIG) was digested
with BglII and CalI to remove IRES and eGFP, and ligased with an
oligonucleotide (50-GATCCGAATTCGTTAACGGATCCGGGCCCAAGCTTCAATT
GGCGGCCGCAGATCTCTCGAGAT-30) containing multiple clone sites, EcoRI,
HpaI, BamHI, ApaI, HindII, MfeI, NotI, BglII, XhoI and ClaI.
Vector MIGm was constructed by introducing IRES-eGFP generated by
PCR with a 50 primer containing an EcroR1 and a 30 primer containing a
MfeI site into the MfeI site of MSCVm vector. MIGm-cMyc was generated by
introducing cMYC released from MSCV-hcMYC-IRES-GFP vector (Addgene,
Cambridge, MA, USA) with EcoRI into EcoRI site of MIGm vector. MIGm-
KRAS12V was made by inserting KRAS12V obtained from T vector with NotI
(blunt) and MfeI into MIGm vector disgested with EcoR1 and HpaI.
Figure 1. cMYC/KRAS12V can transform BaF3 cells independent of IL3 and transduce T2 B cells in vitro. (a) Workflow for generation of the
adoptive plasmacytoma mouse model. (b) Schematic diagram of MSCV-based retroviral vectors: MIG, cMYC, KRAS12V and cMYC/KRAS12V.
(c) Western blot analysis showed expression of MIG, cMYC, KRAS12V and cMYC/KRAS12V in transfected 293T cells. Total protein was analyzed
against human MYC (upper) and RAS (middle); GAPDH (lower) served as a loading control. (d) KRAS12V and cMYC/KRAS12V drove BaF3 cells to
grow independent of IL3 in vitro. Representative cells from two independent experiments are shown. (e) The purification of mouse IgMþ spleen
B cells after micro-bead isolation is shown (left panel). The cell population transited to T2 B-cell subset (IgMþB220þ CD38þ IgDþ ) after
stimulation with LPS and mIL4 for 48h (right three panels). Assays were independently and repeatedly performed. (f ) Colonies in methylcellulose
assays were observed only in cells transduced by cMYC/KRAS12V but not other groups. Three independent experiments were performed.
Figure 2. cMYC/KRAS12V-induced plasmacytoma in BALB/c mice. (a) Recipients receiving MIG- or cMYC- or KRAS12V-transfected donor cells
remained tumor free, whereas all recipients of cMYC/KRAS12V cells died with plasmacytomas. Secondary transplantation recipients of cMYC/
KRAS12V-transduced tumor cells died with similar syndromes (2nd, secondary transplantation). Primary transplantation was repeated five
times, and secondary transplantation was independently and repeatedly performed. Group sizes and survival times are indicated. (b) Tumor in
peritoneal cavity and splenomegaly were observed in the cMYC/KRAS12V group animals (n¼ 20, from five independent experiments). (c) H&E
staining showing tumor cell morphology (n¼ 6). (d) Tumor cells from peritoneal cavity (P.C.) and ascites (A.C.) (n¼ 10) were characterized as
CD138þB220 IgMGFPþ by flow cytometry.
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MSCVm-cMYC-2A-eGFP-IRES-KRAS12V (MIKMG) was made by the
following process: ﬁrst, MSCVm was inserted a 2A sequence (50-GATCCCAG
CTGTTGAATTTTGACCTTCTTAAGCTTGCGGGAGACGTCGAGTCCAACCCCGGG
CC-30), which contains a BamHI and an ApaI competent site at 50 and 30
end, respectively; then, an eGFP coding sequence was inserted into
MSCVm-2A vector, which was generated by PCR with a 50 primer
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containing a ApaI site without its start code sequence and 30 primer
containing an MfeI site; next, IRES element was cloned into MSCVm-2A-
eGFP vector at MfeI site, which was generated by PCR with a 50 primer
containing an EcoR1 site and 30 primer containing an MfeI site; the open
reading frame encoding cMYC generated by PCR from MIG-hcMYC vector
(Addgene, 18119), with a 50 primer containing an EcoR1 site and a
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30 primer containing a BamH1 site without stop coding sequence, was
inserted into MSCVm-2A-eGFP-IRES with EcoRI and BamHI. KRAS12V open
reading frame generated by PCR from pBabe-KRAS12V (Addgene, 12544)
was cloned into MSCVm-cMYC-2A-eGFP-IRES with MfeI and NotI behind
the IRES element.
Viral stock
All DNAs were puriﬁed in CsCl gradients. Lenti-X 293T cells (Clontech
Laboratories, Mountain View, CA, USA) were co-transfected with 10 mg
retroviral vector DNA and 5 mg pCL-Ecotropic packaging vector DNA using
CaCl2 method. Medium was changed at 24 h post transfection, and the
supernatant was harvested at 48 h after transfection. Supernatant was
ﬁltered with 0.45-mm ﬁlters, aliquoted and frozen in a freezer at  80 1C.
The virus titer was determined by transduction of NIH 3T3 cells, and the
percentage of GFPþ cells was screened by ﬂow cytometry. After
calculation, all viruses had titers 44.8 106 GFPþ /ml.
Mouse IgMþ B-cell isolation
All animal experiments were approved by and conformed to the standards
of the Institutional Animal Care and Use Committee at the DFCI. BALB/c or
C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME, USA; 000651)
aged 6–12 weeks were used in all experiments. Mice were killed by
CO2 asphyxiation. Mouse IgM
þ splenic B cells were isolated using
magnetic microbeads and LS MACS separation columns (Miltenyi Biotec,
Cambridge, MA, USA).
Retroviral transfection and transplantation
IgMþ cells were counted and plated at 2 107 cells per 10-cm plate in pre-
stimulation medium of RPMI1640 containing 15% (vol/vol) inactivated fetal
calf serum, 1% (vol/vol) penicillin/ streptomycin, 1.0mg/ml ciproﬂoxacin,
200mM l-glutamine, 10 ng/ml recombinant murine interleukin 4 (mIL4;
Sigma, St Louis, MO, USA), and 50mg/ml lipopolysaccharide (LPS; Sigma).
After pre-stimulation for 24 h, viable cells were counted and transduced
with retroviral stocks in the same medium containing 50% retroviral
supernatant, 10mM Hepes, pH 7.4 and 2 mg/ml polybrene. To increase
transduction efﬁciency, virus and cells were cosedimented at 1000 g for
90min in a Sorvall RT-5.3 centrifuge. Medium was changed after a 3-h
adsorption period. On the next day, a second round of transduction and
cosedimentation was performed using the same conditions. After another
3 h, cells were harvested and 5 105 cells were injected via the lateral tail
vein with 5 105 BM into lethally irradiated recipients.
In vitro proliferation and differentiation assays
For colony assay, 1 105 transfected cells in 100ml were mixed with 3ml
HSC-CUF basic media (Miltenyi Biotec, 130-091-275) in 15-ml tube. Cells
were transferred into six-well cell culture plates with 16-gauge blunt-end
needles (Miltenyi Biotec, 130-091-558), and the plate’s interspace was ﬁlled
with 10ml sterilized phosphate-buffered saline (PBS) to maintain humidity
of the culture environment. Cells were cultured at 37 1C and 5% CO2 for 2
weeks.
Histopathology and immunohistochemistry (IHC)
Tissues were ﬁxed, processed, sectioned and stained with hematoxylin-
eosin by routine methods. Femurs were additionally treated for 1 h in
decalcifying solution (Fisher Scientiﬁc, Cambridge, MA, USA). IHC was
performed according to the standard procedures using rat anti-mouse
CD45R/B220 (RA3-6B2) and rat anti-mouse CD138 (281-2) monoclonal
antibodies obtained from BD Biosciences; anti-cMYC, RAS and eGFP
antibodies obtained from Cell Signaling (Franklin Lakes, NJ, USA); as well as
goat anti-mouse polyclonal antibodies for IgH chains IgA, IgM, IgG and
kappa or lambda light chains conjugated to horseradish peroxidase
(Southern Biotechnology, Birmingham, AL, USA).
Flow cytometry
Red blood cells were removed from single-cell suspensions of peripheral
blood, BM, peritoneal ﬂuid and spleen by RBC lysis buffer. Cells were then
washed once with PBS and stained for 15min at room temperature with
the combination of the following antibodies: IgM-PE, B220-PECy7, CD138-
APC, CD38-PE and IgD-PE washing once with PBS, and then cells were
analyzed on a FACScalibur machine (Becton Dickinson, Franklin Lakes, NJ,
USA) using Cell Quest software (Becton Dickinson).
Western blots
Whole-cell extracts from target cells were prepared, electroblotted onto NC
membranes (Amersham, Wilson, OK, USA) and probed with primary
antibodies according to the standard procedures. The anti-cMYC, RAS and
eGFP antibodies were obtained from Cell Signaling. Following incubation
with horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse
secondary antibody (Cell Signaling, Danvers, MA, USA), bound Igs were
detected using ECL detection solutions (Pierce, Rockford, IL, USA).
Anti-GAPDH served as a loading control.
Southern blot analysis of the IgH gene
Genomic DNA was prepared from IgMþ B cells or cMYC/KRAS12V-induced
plasmacytoma cells with Qiagen DNeasy 96 Blood and Tissue Kit (Qiagen,
Valencia, CA, USA). DNA was digested with EcoRI. Blots were hybridized
with a JH4 probe of the mouse IgH locus. The JH4 probe was generated by
PCR using a plasmid containing a 1.9 BamHI-EcoRI genomic fragment of
mouse heavy-chain locus as template and primers JH4f (50-TACTATGC-
TATGGACTACTGG-30) and JH4r (50-CTCTCCAGTTTCGGCTGAATC-30). South-
ern blot hybridization was performed as described.22
Gene expression proﬁling
RNA from puriﬁed IgMþ B cells and plasmacytoma cells was extracted with
RNA mini kit (Grand Island, NY, USA), and gene expression proﬁling was
performed using the Affymetrix mouse 430A2.0 gene chip (Affymetrix,
Cleveland, OH, USA). Microarray data were analyzed with OneChannelGUI
package in R workplace. Differential expression was determined using the
LIMMA model. Gene signatures were analyzed with gene set enrichment
analysis (GSEA) in Molecular Signatures Database (MSigDB).
RESULTS
Design of multiple gene expression MSCV-based vectors
To develop an adoptive mouse plasmacytoma model, we puriﬁed
splenic IgMþ B cells, which were cultured with LPS and mIL4 for
24 h. These target cells were transfected twice within 24 h and
then injected via tail vein (intravenous) into lethally irradiated
syngeneic recipients (Figure 1a). To develop oncogene expression
vectors, we modiﬁed the retroviral vector MIG (MSCV-IRES-eGFP) by
inserting multiple cloning sites. We constructed three oncogene
expression vectors: cMYC (50LTR-cMYC-IRES-eGFP-30LTR), KRAS12V
(50LTR-KRAS12V-IRES-eGFP-30LTR) and cMYC/KRAS12V (50LTR-cMYC-
2a-eGFP-IRES-KRAS12V-30LTR). All oncogenes are driven by the
cytomegalovirus type I enhancer and the mouse sarcoma virus
promoter within the 50 LTR (long terminal repeat; Figure 1b). Target
genes were efﬁciently expressed by the vectors in transiently
transfected 293T cells (Figure 1c).
To investigate the biological and functional sequelae of these
oncogenes, we transfected BaF3 cells with MIG, cMYC, KRAS12V or
cMYC/KRAS12V. Two days after transfection, GFPþ cells were
sorted and cultured without IL3. After a week, both KRAS12V and
cMYC/KRAS12V, but not cMYC or MIG alone, drove BaF3 cells
growth in vitro independent of IL3 (Figure 1d). These data suggest
Figure 3. Plasmacytoma cells infiltrated multiple organs. (a) Flow cytometry analysis of GFP and CD138 to track tumor cells in peripheral blood
(PB), femur and tibia BM and spleen (SPL). Numbers represent tumor cell percentage in respective gates. Samples (n¼ 25) of individual mice
from different experiments were analyzed. (b) BM and spleen (SPL) sections from mice receiving MIG-, cMYC-, KRAS12V- and cMYC/KRAS12V-
transfected cells were stained with hematoxylin-eosin (H&E) and anti-CD138 antibody to identify plasmacytoma cells. (c) Liver (LV) sections
from diseased mice were stained with H&E (left) and anti-CD138 antibody (right). (d) IHC analysis of BM sections showed expression of cMYC,
KRAS and eGFP in cMYC/KRAS12V-induced plasmacytoma cells.
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that KRAS12V has the capacity to suppress cMYC-induced
apoptosis in BaF3 cells.
Previous studies have shown that overexpression of oncogenes
cMYC, cMAF and XBP-1 driven by Em promoter in immature B cells
induces plasma cell neoplasms in mice.12–15 Here we used T2
B-cell subset (IgMþB220þCD38þ IgDþ )23 as target cells, which
are generated from stimulating puriﬁed IgMþ B cells with LPS and
mIL4 for 48 h (Figure 1e). To determine whether cMYC-, KRAS12V-
or cMY/KRAS12V-transfected cells could grow in vitro, we
performed soft agar colony assays. T2 B cells transfected with
MIG, cMYC, KRAS12V or cMYC/KRAS12V were seeded in soft agar
culture media, and after 2 weeks, only cMYC/KRAS12V-transduced
cells formed colonies in vitro (Figure 1f). These results suggested
that cMYC/KRAS12V had the capacity to promote independent T2
B cells growth in vitro.
cMYC/KRAS12V induced plasmacytomas in BALB/c mice
To determine whether cMYC/KRAS12V can transform T2 B cells
and induce plasmacytomas in vivo, we transplanted T2 B cells
transfected with MIG, cMYC, KRAS12V or cMYC/KRAS12V into
lethally irradiated syngeneic recipient mice. Only mice that
received cMYC/KRAS12V-transfected T2 B cells developed fatal
tumors within 10 weeks post transplantation (Figure 2a). In
diseased mice, peritoneal tumor, splenomegaly, and ascites
were noted (Figure 2b). Tumor cells had dispersed nuclear
chromatin, a low nuclear-to-cytoplasmic ratio and amphophilic
cytoplasm with paranuclear hof. Binucleate cells and mitoses
were rarely observed (Figure 2c). The analyses by ﬂow
cytometry showed tumor cell surface positivity for GFP and
CD138, but absence of IgM and B220 (CD138þB220 IgM
GFPþ ) (Figure 2d). These features and phenotypes resemble
previously reported transgenic and chemically induced plas-
macytoma mouse models.24,25 We also tested whether cMYC/
KRAS12V-transformed plasmacytoma cells could cause similar
tumors in secondary transplant recipients. In these experiments,
splenic tumor cells from diseased mice were transferred into
syngeneic mice, and all recipients developed tumors within 4
weeks (Figure 2a).
In chemically induced plasmacytoma mouse models, plas-
macytoma cells are typically located at the site of injection and
infrequently metastasize to BM and other organs.26,27 In MM
patients, tumor cells frequently affect BM and kidney, but
rarely directly inﬁltrate other organs. To further deﬁne the
anatomic distribution of plasmacytoma cells in our model, cells
isolated from the peripheral blood, BM and spleen were
analyzed for eGFP and CD138 expression. We found that
plasmacytoma cells inﬁltrated BM (30–50%) and spleen
(10–70%) and, to a lesser (p 0.3% of total cells) extent, in
peripheral blood (Figure 3a). Only cMYC/KRAS12V mice
developed plasmacytomas with tumor cell inﬁltration in the
BM and spleen. All tumor cells have similar cell morphology
and surface phenotype (Figures 3b and c).
To determine the contribution of cMYC and KRAS12V in
plasmacytoma development, we performed IHC assays with
antibodies speciﬁc for cMYC, KRAS and GFP on BM specimens.
Positive staining for cMYC, KRAS and GFP were conﬁrmed in
plasmacytoma cells within tissues from cMYC/KRAS12V, but not
MIG, cMYC or KRAS12V, mice (Figure 3d).
Hypergammaglobulinemia, renal and bone alterations in diseased
mice
A characteristic feature of MM and other plasma cell neoplasms
is secretion of monoclonal Ig, detected as a distinct band
(M-spike) by serum protein electrophoresis. In our model,
M-spikes were detected in both the serum and ascites in cMYC/
KRAS12V mice, but not in the serum of others (MIG, cMYC and
KRAS12V) (Figure 4a and data not shown). The Ig chain isoforms
in diseased mice include IgG1, IgM and IgA heavy chains and
both of k and l light chains (Figure 4b). Southern blot analysis
of IgH gene rearrangement in plasmacytoma cells indicated
that cMYC/KRAS12V-induced plasmacytomas were clonal
(Figure 4c).
In human MM, development of Ig heavy and light chain, as well
as inﬁltration of tumor cells, leads to both renal tubular
obstruction and glomerular damage. We observed glomerular
shrinkage in cMYC/KRAS12V mice but not in other groups
(Figure 5a). These renal lesions were similar to pathological
manifestations in MM.28 To assess Ig deposition, we performed
IHC assays with antibodies speciﬁc for mouse Igs IgG, IgM, k and l.
Ig chains were deposited in both the tubules and glomerulus
(Figure 5b).
Another hallmark of human MM is osteolytic bone lesions. To
determine whether the bone lesions developed in diseased mice,
we examined bone structure changes with micro-computed
tomography (micro-CT). No bone osteolysis was detected, even
in the cMYC/KRAS12V group mice (Figure 5c).
Gene expression proﬁling in cMYC/KRAS12V-induced
plasmacytoma cells
To gain further insights into the roles of cMYC/KRAS12V in
tumorigenesis and identify the tumor type, we analyzed the gene
expression signatures of cMYC/KRAS12V-induced tumor cells by
using global transcriptional proﬁling analysis and comparing
tumor cells to syngeneic murine IgMþ B cells. Genes were
considered signiﬁcantly altered based on more than twofold
change in mean expression (Po0.05). Using these criteria, 4466
Figure 4. Evidence of clonality and hypermutation of expressed Ig
genes in cMYC/KRAS12V-induced plasmacytoma mice. (a) Serum
protein electrophoresis (SPEP) in serum and ascites from cMYC/
KRAS12V-induced plasmacytoma mice. The bands are indicated
with arrows. Samples were obtained from all the group animals as
labeled (n¼ 5 each group). (b) Ig isoform identification. Ascites were
collected from plasmacytoma mice and analyzed with Thermo
Scientific Pierce Rapid ELISA Mouse mAb Isotyping Kit. The Ig
isoforms (n¼ 10) are represented by color labeled bands as
indicated. (c) Southern blot analysis for clonotypic IgH -chain
rearrangement in plasmacytoma cells. Genomic DNA was isolated
from IgMþ B cells (sample 1) or cMYC/KRAS12V-induced plasmacy-
toma cells (samples 2–7), digested with EcoRI restriction enzyme
and hybridized with murine JH4 probe. GL denotes germline band.
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genes were signiﬁcantly altered in tumor cells: 2333 were
upregulated and 2133 were downregulated. Transcription factors
required for plasma cell differentiation and survival were
signiﬁcantly increased: PRDM1 (Blimp-1), IRF4 and XBP-1 were
increased 5.9-, 4.8- and 3.6-fold, respectively. Conversely, B-cell
transcription factors absent or downregulated in plasma cells,
including BCL-6, CIITA, MTA3, EBF1, STAT3, PAX5 and SPIB, were
also signiﬁcantly downregulated in plasmacytoma cells
(Supplementary Data, Supplementary Table S1). Expression of
several hallmark plasma cell differentiation and survival genes
were conﬁrmed using quantitative real-time PCR (Figure 6a).
GSEA also revealed signiﬁcant enrichments for upregulation of
genes related to plasma cell differentiation and survival (Figure 6b,
Supplementary Figure S1A), whereas gene sets related to B-cell
receptor signaling were downregulated (Figure 6d). As expected,
genes regulated by IRF4 and XBP1 were signiﬁcantly upregulated
(Figure 6e and Supplementary Figures S1B and C). Finally, several
components of the nuclear factor-kB (NF-kB) pathways, including
NF-kB1 and NF-kB2, and Rel, RelA and RelB were also down-
regulated in tumor cells (Figure 6f and Supplementary Figure S1D).
These data are consistent with previous comparison of plasma cells
versus IgMþ B cells.29–32
To conﬁrm the functional roles of cMYC and KRAS12V in
plasmacytoma genesis, we performed GSEA with four well-
established canonical transcriptional signatures of MYC-depen-
dent genes.26,33–35 Most genes in these gene sets were
signiﬁcantly upregulated in plasmacytoma cells (Figure 7a and
Supplementary Figure S2A). Previous studies have demonstrated
that RAS suppressed cMYC-induced apoptosis via activating PI3K/
AKT pathway.36 Activated AKT in turn phosphorylates and
activates mammalian target of rapamycin (mTOR), an essential
component of mTORC1 that promotes tumor cell proliferation and
survival.37 In cMYC/KRAS12V-transduced plasmacytoma cells,
genes in mTOR target gene set38 were signiﬁcantly upregulated
(Figure 7b and Supplementary Figure S2B). These results further
conﬁrm the formation of plasmacytoma due to cooperation of
cMYC and KRAS12V. As in other tumors, genes regulating cell
cycle,39 as well E2F40 target genes, and genes suppressed by RB141
were also signiﬁcantly upregulated (Supplementary Figure S2C).
Apoptotic signaling was inhibited by cMYC/KRAS12V: speciﬁcally,
genes suppressed by P53 and P73 during cell growth arrest and
apoptosis were enriched and upregulated in plasmacytoma cells
(Figure 7c and Supplementary Figure S2C). Several other gene sets
were also enriched and upregulated plasmacytoma cells, including
Figure 5. Renal and bone alterations in cMYC/KRAS12V-induced plasmacytoma mice. (a) Renal tissue from mice receiving MIG-, cMYC-,
KRAS12V- and cMYC/KRAS12V-transfected cells (n¼ 3 each group) were analyzed by light microscopy (hematoxylin-eosin staining) and IHC
staining with antibodies against mouse Ig k chains. (b) Histological sections of kidneys of mice receiving cMYC/KRAS12V-transduced
plasmacytomas were analyzed by IHC staining with antibodies against mouse Ig k and l light chains, as well as IgG and IgM heavy chains.
(c) Micro-CT analysis demonstrated no bone lesions in all the group animals. Representative graphs from three individual animals are shown.
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EZH2,42 NRF243 and YAP44 (Figure 7d). These results provide further
insight into the role of cMYC/KRAS12V in plasmacytoma pathogen-
esis and identify potential therapeutic targets.
Identifying provirus integration sites and altered genes
Single oncogene transgenic MM mouse models may have long
disease latency until the development of disease, as additional
genetic lesions and/or epigenetic dysregulations in tumor-initiating
cells may be required for tumor development.12,13 In an
adoptive model, provirus integration into host genome can alter
host-cell gene expression.45 To determine whether provirus
integrations are involved in the pathogenesis in our model, we
identiﬁed MSCV integration sites using ligation-mediated PCR
method. In total, we identiﬁed 11 retroviral integration sites
in three diseased mice (n¼ 3, 2–4 clones in each tumor
sample Figure 8a). The integration sites are not recurrent, and
Figure 6. Plasma cell transcription signatures in cMYC/KRAS12V-transduced plasmacytoma cells. (a) Expression of selected genes from
microarray results were confirmed using quantitative real-time PCR. All data represent mean of triplicate experiments. (b) GSEA showed a
plasma cell gene expression signature of plasmacytoma cells. (c) GSEA showed genes associated with B-cell receptor signaling to be
significantly downregulated in plasmacytoma cells. (d) GSEA showed genes in IRF4 target gene set were upregulated in plasmacytoma cells.
(e) Table of the gene sets related to plasma cell differentiation and survival.
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there is no evidence indicating an association with MM (Figure 8b).
These data indicate that the plasmacytomas derived by MSCV-
cMYC/KRAS12V did not require additional genetic lesions.
DISCUSSION
Here we report a rapid-onset high-penetrance mouse model of
plasmacytoma based on enforced expression of both cMYC and
KRAS12V in T2 B subset population cells via retroviral transduction,
followed by transplantation into lethally irradiated mice. The
disease latency was about 7 weeks, all recipients developed
disease, and most recipients died within 10 weeks. Compared with
transgenic models, this adoptive model signiﬁcantly reduces both
time and cost and provides a highly efﬁcient system to evaluate
oncogenes. Moreover, it is feasible to combine oncogenes
to study their cooperation effects. Conversely, we can introduce
RNA-interfering techniques to suppress the expression of speciﬁc
targets associated with oncogenes. This rapid model therefore
provides a faithful in vivo system to functionally evaluate the
genetic lesions in cancer, both elucidating pathogenesis and
evaluating therapeutic targets.
We selected cMYC and KRAS12V as examples to examine
the possibility that enforced expression of oncogenes in a
speciﬁc B-cell population could model plasmacytoma in mice.
Deregulated activity of cMYC is highly associated with MM,26 and
previous transgenic mouse models and chemically induced
plasmacytomas in BALB/c mice have demonstrated the roles of
cMYC in the development of plasmacytomas.46 KRAS as a
secondary oncogene was selected as KRAS mutations can
suppress cMYC-induced apoptosis in rat ﬁbroblasts via
PI3K/AKT signaling, and KRAS mutations are frequently
detected in MM.36 Moreover, previous studies showed that
KRAS12V could enhance cMYC-induced apoptosis via
constitutively activating Raf pathway in rat ﬁbroblasts.36 Of
note, v-myc and v-raf had synergistic roles in plasmacytomas in
BALB/c mice induced by pristine priming,21,47 suggesting that
the role of Raf signaling might vary with cell types or genetic
backgrounds. As expected, KRAS12V efﬁciently suppressed
cMYC-induced apoptosis in a pre-B-cell line (murine BaF3 cells)
in vitro and successfully induced plasmacytomas in vivo by
cooperating with cMYC. Finally, in our adoptive mouse model,
neither cMYC nor KRAS12V alone was sufﬁcient to induce
plasmacytomas in BALB/c mice. Previous transgenic mouse
models already indicate that secondary mutations are required
for the development of plasmacytomas contributing to their
long latency time.13 Here, we provide KRAS12V as a required
secondary gene lesion, which signiﬁcantly reduces disease
latency time.
Figure 7. Gene expression signatures of cMYC/KRAS12V-transduced plasmacytoma cells. (a) Using GSEA, four gene sets associated with MYC
activation are presented in plasmacytoma cells compared with IgMþ B cells. (b) GSEA showed genes upregulated by mTOR in plasmacytoma
cells. (c) GSEA showed that genes regulating cell cycle are significantly enriched in plasmacytoma cells. (d) Table of gene sets of MYC, mTOR,
cell cycle and cancer-related pathways (from top to bottom) in cMYC/KRAS12V-transduced plasmacytoma cells.
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The target cell population is critical for successful induction of
plasmacytoma in recipients. Puriﬁed splenic IgMþ population
includes immature B cells, early transitional B cells (T1 B cells), later
transitional B cells and memory B cells.23 After stimulation with
LPS and mIL4, the major cell population transits to T2 B-cell subset
(IgMþB220þCD38þ IgD). In this model, T2 B cells were
transformed by cMYC/KRAS12V and induced plasmacytoma
in vivo based on both cell morphology and cell surface
biomarkers (CD138þB220 IgMGFPþ ). Gene proﬁling also
indicated that tumor cells acquire plasma cell and lose IgMþ
B-cell gene expression signatures. Speciﬁcally, plasma cell
differentiation genes were signiﬁcantly upregulated, whereas
B-cell-speciﬁc transcription factors were repressed. These results
are consistent with previous gene proﬁling studies comparing
plasma cells with IgMþ B cells.29
Although the adoptive mouse model does not accurately reﬂect
all the features of human MM, it recapitulates many major
characteristics of the disease. In our cMYC/KRAS12V-induced
plasmacytoma mouse model, some mice developed hind limb
paralysis with plasma cell inﬁltration of the spine. Histological
examination of femur also showed tumor cell inﬁltration at
multiple loci in BM. The lack of lytic bone lesions observed with
micro-CT may be associated with lethal irradiation48 or could be
manifested at later points of time. Other MM features, such as
hyperglobulinemia and renal injury, were mimicked in this model.
After secondary transplantation of cMYC/KRAS12V-induced
plasmacytomas, all recipients developed disease at short latency,
21 days post transplantation compared with 70 days primary
transplantation recipients. The major disease features of sec-
ondary transplant recipients resemble those in primary trans-
plant recipients. Thus, secondary transplant recipients may
represent an even more suitable system for preclinical drug
evaluations.
Previous studies have demonstrated that chemically induced
plasmacytoma are mouse strain speciﬁc.49 Consistent with these
ﬁndings, we ﬁnd that BALB/c, but not C57BL/6, mice are
susceptible to cMYC/KRAS12V-induced plasmacytoma. This
provides us a way to investigate the role of tumor-suppressor
genes in MM pathogenesis, such as P53 and RB1. For example, in
both human MM and murine plasmacytoma, loss of function of
P53 or RB1 is commonly observed. Thus, our model could be used
to determine whether P53 or RB1 has a critical role in preventing
the development of cMYC/KRAS12V-induced plasmacytoma.
In summary, this adoptive plasmacytoma mouse model
faithfully reﬂects most of the major characteristics of MM in
patients. It affords a system to evaluate the oncogenic events in
MM, elucidate mechanism of these events and identify potential
targets for future therapy. It will also be useful to study
microenvironmental and epigenetic factors in MM, as well as
assess potential targeted therapies.
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